|ACADIA Pharmaceuticals Inc.|
3611 Valley Centre Drive
United States - Map
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimers disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
|ACADIA Pharmaceuticals Inc.’s ISS Governance QuickScore as of Jun 1, 2016 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Stephen R. Davis J.D.,
Chief Exec. Officer, Pres and Director
|Mr. Glenn F. Baity ,
Exec. VP, Gen. Counsel and Sec.
|Mr. Terrence O. Moore ,
Chief Commercial Officer and Exec. VP
|Dr. Srdjan Stankovic M.D., MSPH,
Head of R&D and Exec. VP
|Ms. Teri L. Chuppe ,
VP of Fin.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|